Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
Merck
Mallinckrodt
Express Scripts
Colorcon

Last Updated: December 6, 2022

CLINICAL TRIALS PROFILE FOR NELARABINE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Nelarabine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002970 ↗ 506U78 in Treating Patients With Refractory Hematologic Cancer Completed Children's Cancer Group Phase 2 1997-06-01 Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
NCT00002970 ↗ 506U78 in Treating Patients With Refractory Hematologic Cancer Completed National Cancer Institute (NCI) Phase 2 1997-06-01 Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
NCT00003545 ↗ 506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Completed Southwest Oncology Group Phase 2 1998-08-01 Phase II trial to study the effectiveness of 506U78 in treating patients with refractory or relapsed acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
NCT00003545 ↗ 506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Completed National Cancer Institute (NCI) Phase 2 1998-08-01 Phase II trial to study the effectiveness of 506U78 in treating patients with refractory or relapsed acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
NCT00003635 ↗ 506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents Completed National Cancer Institute (NCI) Phase 2 1999-01-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of 506U78 in treating patients with chronic lymphocytic leukemia that has not responded to fludarabine or alkylating agents.
NCT00003635 ↗ 506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents Completed GlaxoSmithKline Phase 2 1999-01-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of 506U78 in treating patients with chronic lymphocytic leukemia that has not responded to fludarabine or alkylating agents.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Nelarabine

Condition Name

Condition Name for Nelarabine
Intervention Trials
Leukemia 7
Acute Lymphoblastic Leukemia 4
Lymphoblastic Lymphoma 4
Lymphoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Nelarabine
Intervention Trials
Precursor Cell Lymphoblastic Leukemia-Lymphoma 19
Leukemia, Lymphoid 19
Leukemia 19
Lymphoma 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Nelarabine

Trials by Country

Trials by Country for Nelarabine
Location Trials
United States 176
Canada 12
Germany 12
Australia 8
France 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Nelarabine
Location Trials
Texas 13
California 11
Ohio 8
New York 7
Illinois 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Nelarabine

Clinical Trial Phase

Clinical Trial Phase for Nelarabine
Clinical Trial Phase Trials
Phase 3 4
Phase 2/Phase 3 1
Phase 2 12
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Nelarabine
Clinical Trial Phase Trials
Completed 12
Recruiting 9
Terminated 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Nelarabine

Sponsor Name

Sponsor Name for Nelarabine
Sponsor Trials
National Cancer Institute (NCI) 13
GlaxoSmithKline 6
M.D. Anderson Cancer Center 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Nelarabine
Sponsor Trials
Other 21
Industry 20
NIH 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
McKesson
Colorcon
Harvard Business School
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.